| P2093 | author name string | Claire Harrison | |
| | Donal McLornan | |
| | Sofia Galli | |
| P2860 | cites work | The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo | Q43451422 |
| | Progressive multifocal leukoencephalopathy associated with ruxolitinib | Q44509111 |
| | Bilateral toxoplasmosis retinitis associated with ruxolitinib | Q44909357 |
| | Reactivation of hepatitis B virus infection following ruxolitinib treatment in a patient with myelofibrosis. | Q45350105 |
| | Rapid and long-lasting decrease of T-regulatory cells in patients with myelofibrosis treated with ruxolitinib. | Q46891342 |
| | Population pharmacokinetic analysis of orally-administered ruxolitinib (INCB018424 Phosphate) in patients with primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF) or post-essential thrombocythemia myelofibrosis (PET MF). | Q50990686 |
| | Ruxolitinib is a potent immunosuppressive compound: is it time for anti-infective prophylaxis? | Q54393708 |
| | The pharmacokinetics, pharmacodynamics, and safety of orally dosed INCB018424 phosphate in healthy volunteers. | Q54618299 |
| | Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2 | Q24568313 |
| | Jakpot! New small molecules in autoimmune and inflammatory diseases | Q27001957 |
| | Constitutive activation of STAT transcription factors in acute myelogenous leukemia | Q28207618 |
| | An essential role for interferon gamma in resistance to Mycobacterium tuberculosis infection | Q29616521 |
| | Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis | Q33391880 |
| | Serious adverse events during ruxolitinib treatment discontinuation in patients with myelofibrosis | Q33397838 |
| | JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis | Q33399977 |
| | A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis | Q33399980 |
| | A phase I study of panobinostat (LBH589) in patients with primary myelofibrosis (PMF) and post-polycythaemia vera/essential thrombocythaemia myelofibrosis (post-PV/ET MF). | Q33405372 |
| | Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis | Q33411211 |
| | Romiplostim-induced myelofibrosis | Q33411218 |
| | A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea | Q33411637 |
| | Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts | Q33411755 |
| | Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms | Q34021151 |
| | Kinase domain mutations confer resistance to novel inhibitors targeting JAK2V617F in myeloproliferative neoplasms | Q34021753 |
| | Metabolism, excretion, and pharmacokinetics of [14C]INCB018424, a selective Janus tyrosine kinase 1/2 inhibitor, in humans | Q34023419 |
| | Somatic mutations of calreticulin in myeloproliferative neoplasms | Q34039270 |
| | An opportunistic infection associated with ruxolitinib, a novel janus kinase 1,2 inhibitor | Q34343220 |
| | Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis. | Q36003480 |
| | Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia | Q36352535 |
| | Scouting out the neighborhood in AIDS-related lymphoma | Q37026748 |
| | Establishing optimal quantitative-polymerase chain reaction assays for routine diagnosis and tracking of minimal residual disease in JAK2-V617F-associated myeloproliferative neoplasms: a joint European LeukemiaNet/MPN&MPNr-EuroNet (COST action BM090 | Q37250169 |
| | Comparison of placebo and best available therapy for the treatment of myelofibrosis in the phase 3 COMFORT studies | Q37552023 |
| | Genetic and epigenetic complexity in myeloproliferative neoplasms | Q37967274 |
| | Allogeneic stem cell transplantation for myelofibrosis in 2012. | Q37998567 |
| | Ruxolitinib for the treatment of myelofibrosis: a NICE single technology appraisal. | Q38133381 |
| | Therapeutic targeting of the Jak/STAT pathway. | Q38155957 |
| | Resolution of bone marrow fibrosis in a patient receiving JAK1/JAK2 inhibitor treatment with ruxolitinib | Q38444153 |
| | Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy | Q38824881 |
| | Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report | Q40045490 |
| | Health-related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapy | Q40247865 |
| | Management of cytopenias in patients with myelofibrosis treated with ruxolitinib and effect of dose modifications on efficacy outcomes | Q41836418 |
| | Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia | Q42720284 |
| | A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process | Q43237567 |
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | myelofibrosis | Q1752571 |
| | ruxolitinib | Q7383611 |
| P304 | page(s) | 967-976 | |
| P577 | publication date | 2014-06-04 | |
| P1433 | published in | Expert Opinion on Drug Safety | Q5421206 |
| P1476 | title | Safety evaluation of ruxolitinib for treating myelofibrosis | |
| P478 | volume | 13 | |